Sydys Corp. Announces Publication of Phase 2b CVac™ Data Against Ovarian Cancer... Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present


Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, May 19, 2016

Sydys Corp. Announces Publication of Phase 2b CVac™ Data Against Ovarian Cancer...

financial news

 Source: Sydys Corporation
SEATTLE, May 18, 2016 (GLOBE NEWSWIRE) -- Sydys Corporation (OTCQB:SYYC), a clinical stage biotechnology company focused on the development of immunotherapies, today announced the publication of findings from a study demonstrating the potential of CVac™ in ovarian cancer in the Journal for ImmunoTherapy of Cancer.
The study entitled “Progression-free and overall survival in ovarian cancer patients treated with CVac™, a mucin 1 dendritic cell therapy in a randomized Phase 2b trial was led by Dr Heidi Gray at the University of Washington Medical Center, WA, USA with Dr Jeffrey C Goh of Greenslopes Private Hospital, Queensland, Australia and included several universities and institutions in the United States and Australia (NCT01068509), including;
  • Scripps Cancer Center, San Diego, CA
  • Peter MacCallum Cancer Centre, East Melbourne Vic, Australia
  • Cleveland Clinic Foundation, Cleveland, OH
  • Duke Cancer Institute, Duke University Health System, Durham, NC
  • University of California, San Francisco & Sutter Health Research Institute, San Francisco, CA
  • Stanford University Cancer Institute, Stanford, CA
The publication outlines results obtained from a Phase 2b clinical trial evaluating the safety, efficacy and immune outcomes of CVac™ in patients with advanced epithelial ovarian cancer.
The randomized, open label trial enrolled 56 patients undergoing first or second clinical remission. Twenty seven patients received the standard of care, while 20 patients received CVac™, a mucin 1 targeted-dendritic cell (DC) treatment as a maintenance therapy, over a period of 56 weeks. The primary endpoint was efficacy measure through progression free survival (PFS), while the secondary endpoint included overall survival (OS).....


Post a Comment

Your comments?